Christopher Chew

University of North Carolina at Chapel Hill

Papers

Total Citations

H-Index

About

Christopher Chew is a prominent urologic oncologist and researcher whose work centers on precision medicine in prostate cancer, particularly through genomic risk stratification. His major contributions focus on validating the clinical utility of the Oncotype DX Genomic Prostate Score, a tumor-based gene expression assay that predicts adverse pathology and disease aggressiveness. In his landmark 2021 study, Chew demonstrated a strong association between higher Genomic Prostate Scores and unfavorable tumor characteristics at radical prostatectomy, including upgrading and upstaging, providing critical evidence for integrating genomic testing into treatment decision-making. This work, cited 38 times, has helped refine the use of molecular diagnostics to reduce overtreatment of indolent cancers while identifying high-risk patients who benefit from immediate intervention. Chew’s research bridges the gap between genomic biomarkers and surgical pathology, offering clinicians a more precise tool for personalizing prostate cancer management. His findings have been influential in shaping guidelines for active surveillance and surgical planning, underscoring his role as a key contributor to the shift toward molecularly informed urologic oncology.